arrow
Þ

Þorvarður R. Hálfdánarson

Mayo Clinic
H指数:50
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma

II期研究: futibatinib联合pembrolizumab治疗FGF19表达型晚期肝细胞癌患者的疗效观察

2026-08-250
OAAI
Outcomes of liver resections for neuroendocrine tumor liver metastases in carcinoid heart disease

神经内分泌肿瘤肝转移合并类癌心脏病患者肝切除的预后

2026-08-190
PRE
Using a participation monitoring database to enhance recruitment in a rare cancer population

利用参与监测数据库提高罕见癌症人群的招募

2026-02-130
OAAI
Outcomes of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Patients with Metastatic Pheochromocytoma and Paraganglioma

177Lu-DOTATATE肽受体放射性核素治疗在转移性嗜铬细胞瘤和副神经节瘤患者中的疗效

2026-01-010
PRE
ASO Visual Abstract: Carcinoid Syndrome Impacts Long-Term Outcomes After Hepatectomy for Small Bowel Neuroendocrine Tumor Liver Metastasis

ASO视觉摘要:类癌综合征影响小肠神经内分泌肿瘤肝转移行肝切除术后长期预后

2025-11-030
PRE
Carcinoid Syndrome Impacts Long-Term Outcomes After Hepatectomy for Small Bowel Neuroendocrine Tumor Liver Metastasis

类癌综合征影响小肠神经内分泌肿瘤肝转移行肝切除后的长期结局

2025-10-030
PRE
Cause of death after cytoreductive hepatectomy for neuroendocrine tumor liver metastases: a single center retrospective analysis

神经内分泌肿瘤肝转移灶减瘤性肝切除术后死亡原因:一项单中心回顾性分析

2025-06-210
PRE
Alternative lengthening of telomeres and Ki-67 proliferation index provide complementary information on recurrence risk after resection of pancreatic neuroendocrine tumors

端粒的替代延长和Ki-67增殖指数提供了胰腺神经内分泌肿瘤切除术后复发风险的补充信息

2025-02-130
PRE